TL1A Gene Variants and Crohn's Disease in Jewish Patients
Author Information
Author(s): Michelsen Kathrin S., Thomas Lisa S., Taylor Kent D., Yu Qi T., Mei Ling, Landers Carol J., Derkowski Carrie, McGovern Dermot P. B., Rotter Jerome I., Targan Stephan R.
Primary Institution: Cedars-Sinai Medical Center
Hypothesis
Does the TL1A gene haplotype influence the severity of Crohn's disease in Jewish patients?
Conclusion
TL1A gene variation increases the expression of TL1A protein in response to immune stimulation, which may worsen chronic intestinal inflammation in Jewish Crohn's disease patients.
Supporting Evidence
- TL1A haplotype B was found to be more frequent in Jewish Crohn's disease patients with severe disease.
- Jewish patients with haplotype B had higher levels of TL1A expression in response to immune stimulation.
- TL1A may serve as a therapeutic target for treating Crohn's disease in specific patient subgroups.
Takeaway
Some people have a gene that makes their body react more strongly to certain infections, which can make their stomach problems worse.
Methodology
The study involved collecting blood samples from Crohn's disease patients and analyzing the expression of TL1A in response to immune stimulation.
Potential Biases
Potential bias due to the ethnic specificity of the sample population.
Limitations
The study primarily focused on Jewish patients, which may limit the generalizability of the findings to other populations.
Participant Demographics
Participants included Jewish and non-Jewish Crohn's disease patients, with a focus on Ashkenazi Jews.
Statistical Information
P-Value
p≤0.001
Statistical Significance
p≤0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website